Russia masterminds its International Medical Cluster — for now only for Moscow
18 June 2015
The State Duma, the lower house of Russian Parliament, passed a draft bill on the development of an “International Medical Cluster” in Russia. The stated goals of the new effort include further medical development, transfer of advanced technologies into Russia, and the providing of high-quality medical assistance for populations.
Moscow and Australian scientists improve lives with ultra-resilience
18 June 2015
A consortium of Prof. Sergei Prokoshkin led group of Russian scientists at MISiS, a leading Russian university based in Moscow, and experts from Endogene-Globetek, an Australian company, has tapped into the physical effect of shape-memory and ultra-resilience alloys to develop innovation technologies, the MISiS website announced .
Celtaxsys $40.00 million Fundraising. William P Reddick Submitted Jun 10 SEC Form
17 June 2015
Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
So A New Drug Takes $1 Billion?
17 June 2015
First, let’s consider toning down the billion-dollar baying; it’s become a confused expression of sardonic triumph: “Well, they say it takes a billion dollars to get a new drug nowadays! Harrumph!”
Branded pharma worries, generics makers cheer as trade pact hits snag in Congress
17 June 2015
The Trans-Pacific Partnership took it on the chin Friday when the U.S. House voted against a key assistance program for workers displaced by global trade. That move throws a wrench into U.S. efforts to pass the controversial trade agreement, which pharma companies have lobbied hard to shape.
MSF wants Indian PM to stand up to Big Pharma peer pressure
17 June 2015
Western drugmakers have long struggled with India's populist attitude toward patents, and hoped there would be some light at the end of the tunnel with the latest spate of trade negotiations over generic drugs in the country. But Doctors Without Borders (MSF), a vocal critic of Big Pharma's patent tactics, is none too pleased with the proposed trade changes.
Pharma M&A and Financial Trends: The Frenzy and Risks Escalate
17 June 2015
Every day the newspapers are filled with stories about the pharma industry. Many are very positive, with reports of breakthroughs and novel approaches to solving difficult health issues, the commitment of the industry to attack some of the most difficult diseases and break through a myriad of structural roadblocks and escalating development costs. Others are more critical with complaints about drug pricing, the seemingly endless stream of take-overs, and the rush towards orphan drugs.
Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
16 June 2015
Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Administration (FDA) on its lead drug triamcinolone acetonide (TA) administered via injection into the suprachoroidal space (SCS) for the treatment of macular edema associated with non-infectious uveitis. Agreement was reached with the FDA for the overall development plan with a single pivotal Phase 3 clinical trial, and the company is finalizing plans to initiate this global study.
Tobira Finishes Patient Enrollment for NASH Study
16 June 2015
Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAURstudy, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company, which is focused on developing and commercializing therapeutic options to treat liver and inflammatory conditions, announced enrollment completion in a press release.
Coda Therapeutics $3.43 million Fundraising. David Pool Published Jun 12 SEC Filing
16 June 2015
Coda Therapeutics Inc, Corporation just submitted form D announcing $3.43 million debt financing. This is a new filing. Coda Therapeutics was able to finance itself with $1.21 million so far. That is 35.16% of the financing offer. The total private financing amount was $3.43 million. The form was filled on 2015-06-12. The reason for the financing was: Total Offering Amount includes estimated amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer’s preferred stock (assuming no net issue exercise, where applicable).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024